Viridian Therapeutics (VRDN) AI Stock Analysis

• Market Cap: $1.38B
• Dividend Yield: N/A
• Average Volume (3M): 693.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.59
• Revenue Growth: 5.90%
• EPS Growth: -0.36%
• Country: US
• Employees: 143
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -1.00
• Shares Outstanding: 81,662,370
• 10 Day Avg. Volume: 815,780
• 30 Day Avg. Volume: 693,555
• PEG Ratio: 0.19
• Price to Book (P/B): 1.94
• Price to Sales (P/S): 4309.19
• P/FCF Ratio: -5.59
• Enterprise Value/Market Cap: 0.57
• Enterprise Value/Revenue: 3.43K
• Enterprise Value/Gross Profit: 7.38K
• Enterprise Value/Ebitda: -2.27
• 1Y Price Target: $36.88
• Price Target Upside: 105.23% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14

• Rating: 57 Neutral
• Price Target: $17.50 ▼(-2.62% Downside)

The overall stock score for Viridian Therapeutics is primarily influenced by financial performance challenges and valuation concerns, which are offset to some extent by positive technical indicators and significant corporate events. The partnership with Kissei and positive trial results are promising, but financial and valuation metrics remain key risks.

Positive Factors

Financial Position

Viridian Therapeutics holds a strong cash position, with cash and equivalents of $563M, providing financial stability.

Regulatory Milestones

Veli recently received Breakthrough Therapy Designation based on its robust and rapid improvements on clinical manifestations for thyroid eye disease.

Strategic Partnerships

VRDN announced an exclusive license agreement with Kissei Pharmaceutical to develop and commercialize Veli and VRDN-003 in Japan, providing important clinical and regulatory validation.

Negative Factors

Market Competition

The company needs to establish meaningful differentiation for VRDN-006 to gain more credit, as they are behind in the FcRn space.

Stock Performance

Shares are down -18% year-to-date compared to the broader index due to the lack of catalysts in 2025, with more value-creating catalysts expected in 2026.

Viridian Therapeutics Business Overview & Revenue Model

Company Description

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Viridian Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company may earn money through several key revenue streams, including product sales from approved therapies, milestone payments from partnerships with larger pharmaceutical companies, and potential royalties on future product sales. Significant partnerships with larger biopharmaceutical firms can provide additional financial resources and support for research and development efforts, enhancing the company's ability to bring products to market. Additionally, Viridian may also receive funding through grants or investments aimed at supporting its clinical trials and drug development initiatives.

Viridian Therapeutics Financial Statement Overview

Summary

Viridian Therapeutics faces financial challenges with declining revenues, negative profitability, and cash flow issues. Despite a strong equity position with low leverage, persistent losses and cash outflows overshadow these strengths, indicating the need for operational improvements.

Income Statement

Viridian Therapeutics shows a declining revenue trend with a significant drop from $2,963,000 in 2021 to $302,000 in TTM 2025. The gross profit margin is negative, indicating cost of goods sold exceeds revenue. Net profit margin is also negative, reflecting substantial losses. EBIT and EBITDA margins are deeply negative, highlighting operational inefficiencies. Overall, the income statement reveals financial instability and a lack of profitability.

Balance Sheet

The balance sheet shows a strong equity position with a high equity ratio of 91.4% in TTM 2025. The debt-to-equity ratio is low, indicating minimal leverage, which is a positive aspect. However, the return on equity is negative due to consistent net losses, reflecting poor shareholder returns. Despite the strong equity base, the company faces challenges in generating profits.

Cash Flow

Operating cash flow is negative, indicating cash outflows from operations. Free cash flow is also negative, reflecting a lack of cash generation after capital expenditures. The operating cash flow to net income ratio is close to 1, suggesting cash outflows are in line with reported losses. The cash flow statement highlights liquidity challenges and the need for external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	230.00K	302.00K	314.00K	1.77M	2.96M	1.05M
Gross Profit	107.00K	302.00K	-1.01M	1.02M	2.34M	-27.25M
EBITDA	-347.27M	-265.66M	-234.56M	-128.63M	-78.79M	-109.67M
Net Income	-344.06M	-269.95M	-237.73M	-125.44M	-79.42M	-110.98M
Balance Sheet
Total Assets	582.32M	742.40M	490.42M	435.09M	203.71M	131.25M
Cash, Cash Equivalents and Short-Term Investments	563.36M	717.58M	477.37M	424.55M	196.97M	127.64M
Total Debt	20.79M	21.09M	21.05M	5.26M	520.00K	455.00K
Total Liabilities	67.16M	70.76M	48.40M	40.03M	15.99M	11.22M
Stockholders Equity	515.17M	671.64M	442.02M	395.06M	187.72M	120.04M
Cash Flow
Free Cash Flow	-309.60M	-232.83M	-185.07M	-94.64M	-54.92M	-29.82M
Operating Cash Flow	-309.06M	-232.32M	-184.17M	-93.84M	-54.58M	-29.78M
Investing Cash Flow	28.20M	-228.65M	-94.25M	-115.13M	-74.29M	-50.48M
Financing Cash Flow	290.52M	457.74M	225.67M	322.24M	125.28M	101.31M

Viridian Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 17.97
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRDN, the sentiment is Positive. The current price of 17.97 is above the 20-day moving average (MA) of 17.15, above the 50-day MA of 16.03, and above the 200-day MA of 16.90, indicating a bullish trend. The MACD of 0.32 indicates Positive momentum. The RSI at 60.28 is Neutral, neither overbought nor oversold. The STOCH value of 53.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VRDN.

Viridian Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	78 Outperform	$1.49B	26.47	17.33%	―	25.59%	―
Sector *	65 Neutral	¥341.96B	10.87	-0.16%	2.41%	10.05%	-9.84%
VRDN	57 Neutral	$1.38B	―	-62.99%	―	5.90%	-0.36%
IOVA	51 Neutral	$712.85M	―	-53.16%	―	636.99%	27.10%
WVE	50 Neutral	$1.29B	―	-171.41%	―	-14.98%	-51.76%
GERN	49 Neutral	$867.70M	―	-31.09%	―	11877.28%	63.14%
SNDX	48 Neutral	$1.08B	―	-113.22%	―	2133.71%	-15.38%

Viridian Therapeutics Corporate Events

Viridian Therapeutics Partners with Kissei for Japan Market

On July 30, 2025, Viridian Therapeutics announced a collaboration and license agreement with Kissei Pharmaceutical to develop and commercialize veligrotug and VRDN-003 in Japan. The agreement includes an upfront payment of $70 million to Viridian, with potential additional milestone payments up to $315 million and tiered royalties on net sales. This partnership combines Viridian’s expertise in thyroid eye disease treatments with Kissei’s experience in rare diseases, aiming to address unmet needs for TED patients in Japan.

The most recent analyst rating on (VRDN) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.

Viridian Therapeutics Stockholders Approve Key Proposals

At the Annual Meeting, Viridian Therapeutics‘ stockholders approved several key proposals, including an amendment to the 2016 Equity Incentive Plan, increasing available shares by 8,000,000. Additionally, all director nominees were elected, and KPMG LLP was ratified as the independent auditor for the fiscal year ending December 31, 2025. The approval of the 2025 Employee Stock Purchase Plan was also confirmed.

The most recent analyst rating on (VRDN) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.

Viridian Reports Positive Phase 3 Trial Results

On May 20, 2025, Viridian Therapeutics announced positive long-term durability data from its THRIVE phase 3 clinical trial for veligrotug, an anti-IGF-1R antibody for thyroid eye disease (TED). The trial showed that 70% of patients maintained their response at week 52, with no changes in safety profile. Veligrotug has received Breakthrough Therapy Designation, and the company plans a Biologics License Application submission in the second half of 2025, with a commercial launch anticipated in 2026.

The most recent analyst rating on (VRDN) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.